Patent Number: 6,166,077

Title: Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1

Abstract: A method is provided for increasing the levels of IGF-1 for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1 selected from the group including neuropathies of the optic nerve and of the olfactory nerve, neuralgia of the trigmeninal nerve, Bell's paralysis, amyotrophic lateral sclerosis, osteoporosis, anthropathy, arthritis, cervical spondylosis and hernia of the intervertebral discs clinical syndromes of reduces height, cachexia and acute or chronic hepatic necrosis, Turner's syndrome, sarcopoenia, growth hormone insensitivity syndromes, obesity, asthenia, myasthenia and heart asthenia, immunodeficiencies and reperfusion injuries, and for the cicatrization of wounds, the healing of ulcers, the treatment of burns, tissue regeneration, cutaneous, intestinal and hepatic tissue regeneration and the formation of dentine, that includes administering, to a patient in need thereof, at least one selected from the group including L-acetylcarnitine, L-isovalerylcarnitine, and L-propionylcarnitine or pharmacologically acceptable salts thereof.

Inventors: De Simone; Claudio (Ardea, IT)

Assignee: Sigma-TAU Industrie Farmaceutiche Riunite S.p.A.

International Classification: A61K 31/21 (20060101); A61K 31/221 (20060101); A61K 031/205 ()

Expiration Date: 12/26/2013